Elaprase Approval History
FDA Approved: Yes (First approved July 24, 2006)
Brand name: Elaprase
Generic name: idursulfase
Dosage form: Injection
Company: Shire plc
Treatment for: Mucopolysaccharidosis Type II
Elaprase (idursulfase) is a purified form of the human lysosomal enzyme iduronate-2-sulfatase produced by recombinant DNA technology. Elaprase is indicated for the treatment of Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II).
Development History and FDA Approval Process for Elaprase
|Jul 24, 2006||Elaprase Shire plc - Treatment for Hunter Syndrome|
|May 17, 2006||Shire Provides Update on U.S. Marketing Application of Elaprase|
|Nov 24, 2005||Shire Files Elaprase (idursulfase) With the FDA for the Treatment of Hunter Syndrome|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.